A single-center long-term experience of active surveillance for prostate cancer: 15 years of follow-up

To describe a single-center 15-year experience of active surveillance (AS) for prostate cancer (PCa). We retrospectively reviewed patients who underwent AS between 2003 and 2018. One hundred fifty-three patients were selected according to the following criteria: (1) biopsy Gleason pattern ≤3+4 with...

Full description

Saved in:
Bibliographic Details
Published inInvestigative and clinical urology Vol. 62; no. 1; pp. 32 - 38
Main Authors Song, Sang Hun, Kim, Jung Kwon, Lee, Hakmin, Lee, Sangchul, Hong, Sung Kyu, Byun, Seok-Soo
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Urological Association 01.01.2021
Korean Urological Association
대한비뇨의학회
Subjects
Online AccessGet full text
ISSN2466-0493
2466-054X
2466-054X
DOI10.4111/icu.20200206

Cover

More Information
Summary:To describe a single-center 15-year experience of active surveillance (AS) for prostate cancer (PCa). We retrospectively reviewed patients who underwent AS between 2003 and 2018. One hundred fifty-three patients were selected according to the following criteria: (1) biopsy Gleason pattern ≤3+4 with (2) ≤two positive core(s) and (3) ≤50% core involvement, clinical-stage ≤T2a, and prostate-specific antigen (PSA) ≤20 ng/mL. Follow-up included PSA measurement every six months, prostate biopsies at one year and then every 2-3 years, and MRI every year. Intervention was triggered by (1) Gleason score (GS) upgrading, (2) >two positive cores, or (3) PSA doubling-time in <3 years. Mean (±standard deviation) follow-up was 36.4 (±31.9) months. Ninety-three (60.8%) and 20 (13.1%) patients received second and third biopsies, respectively. Seventy-two patients (47.1%) discontinued AS for various reasons (59, intervention; 13, follow-up loss). Reasons for intervention consisted of GS upgrading (42.4%), >two positive cores (8.5%), abnormal PSA kinetics (11.9%), and patient preference (37.3%). Notably, 12 (25.5%) patients had pathologic GS ≥4+3 (unfavorable disease) and 3 (6.4%) patients had pathologic stage ≥T3a at radical prostatectomy. Median time to treatment-free survival was 19.5 months. Of the 59 patients who switched to intervention, biochemical recurrence was reported in only one (0.7%) patient. AS is an available option for low-risk PCa in carefully selected patients. Further larger prospective studies are needed to determine the optimal criteria for AS, especially in Korean PCa patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
https://www.icurology.org/pdf/10.4111/icu.20200206
ISSN:2466-0493
2466-054X
2466-054X
DOI:10.4111/icu.20200206